top of page
August 17, 2023
Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain
November 21, 2022
Response Pharmaceuticals Closes $8 Million Series A Financing to Fund Clinical Trials for Patients Suffering from Antipsychotic Induced Weight Gain
Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week
April 23, 2024
bottom of page